[
  {
    "ts": null,
    "headline": "Corrections & Amplifications",
    "summary": "Corrections & Amplifications",
    "url": "https://finnhub.io/api/news?id=a65fc18925ea2cebd354eb0d3dd23285884b0a0ad40c0d3956dce93082e4cf27",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750706400,
      "headline": "Corrections & Amplifications",
      "id": 135499958,
      "image": "",
      "related": "MRK",
      "source": "DowJones",
      "summary": "Corrections & Amplifications",
      "url": "https://finnhub.io/api/news?id=a65fc18925ea2cebd354eb0d3dd23285884b0a0ad40c0d3956dce93082e4cf27"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=04005aab9d4a414abaf1ef96ee178050988798d0f44430c561f765145fedf4e4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750696440,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 135499978,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=04005aab9d4a414abaf1ef96ee178050988798d0f44430c561f765145fedf4e4"
    }
  },
  {
    "ts": null,
    "headline": "High-Quality Dividend Growth Near 52-Week Lows: Salesforce Is Super",
    "summary": "High-Quality Dividend Growth Near 52-Week Lows: Salesforce Is Super",
    "url": "https://finnhub.io/api/news?id=9c56e3b533e7fcb88b86aa11c14282ee6155ecda99a7e8098db10b57ceaa38db",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750686468,
      "headline": "High-Quality Dividend Growth Near 52-Week Lows: Salesforce Is Super",
      "id": 135484400,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9c56e3b533e7fcb88b86aa11c14282ee6155ecda99a7e8098db10b57ceaa38db"
    }
  },
  {
    "ts": null,
    "headline": "Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment",
    "summary": "Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment",
    "url": "https://finnhub.io/api/news?id=be8be3559bf7e0f4eaf87b79a514cd65d1ba6ac4d6f6bab18978ffdc52aa7f3f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750683489,
      "headline": "Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment",
      "id": 135484200,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=be8be3559bf7e0f4eaf87b79a514cd65d1ba6ac4d6f6bab18978ffdc52aa7f3f"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)",
    "summary": "RAHWAY, N.J., June 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. HYPERION met its primary endpoint of time to clinica",
    "url": "https://finnhub.io/api/news?id=3f144384997833335368ab54fb0fee6321194a881da93c3f720c5bbe955679a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750675500,
      "headline": "Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)",
      "id": 135481774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. HYPERION met its primary endpoint of time to clinica",
      "url": "https://finnhub.io/api/news?id=3f144384997833335368ab54fb0fee6321194a881da93c3f720c5bbe955679a6"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Pulmonary Arterial Hypertension Drug Meets Primary Endpoint",
    "summary": "By Adriano Marchese Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received...",
    "url": "https://finnhub.io/api/news?id=48243a899ba024d884e5adc0f3c090e9605674d28160678b89f5fedbbcedb190",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750670535,
      "headline": "Merck's Pulmonary Arterial Hypertension Drug Meets Primary Endpoint",
      "id": 135475146,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Adriano Marchese Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received...",
      "url": "https://finnhub.io/api/news?id=48243a899ba024d884e5adc0f3c090e9605674d28160678b89f5fedbbcedb190"
    }
  },
  {
    "ts": null,
    "headline": "Merck: new positive Phase 3 results in PAH",
    "summary": "Merck reported positive Phase 3 results on Monday in patients with pulmonary arterial hypertension in Group 1 and Functional Class II or III according to the World Health Organization or at high...",
    "url": "https://finnhub.io/api/news?id=e1acffb62b22db17b22c3f78b74b775a3a4c864b61674958e397862a8db14364",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750667367,
      "headline": "Merck: new positive Phase 3 results in PAH",
      "id": 135474781,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck reported positive Phase 3 results on Monday in patients with pulmonary arterial hypertension in Group 1 and Functional Class II or III according to the World Health Organization or at high...",
      "url": "https://finnhub.io/api/news?id=e1acffb62b22db17b22c3f78b74b775a3a4c864b61674958e397862a8db14364"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Phase 3 HYPERION Study of Winrevair Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension",
    "summary": "Merck announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR?? versus placebo in recently diagnosed adults with pulmonary Arterial hypertension functional class II...",
    "url": "https://finnhub.io/api/news?id=99f7bc82c565ff9a2f9f5eceb1805aa81d5d84efc2196823198ceed1eaedad6d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750664136,
      "headline": "Merck Announces Phase 3 HYPERION Study of Winrevair Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension",
      "id": 135474435,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR?? versus placebo in recently diagnosed adults with pulmonary Arterial hypertension functional class II...",
      "url": "https://finnhub.io/api/news?id=99f7bc82c565ff9a2f9f5eceb1805aa81d5d84efc2196823198ceed1eaedad6d"
    }
  }
]